DE60335557D1 - Pharmazeutische zusammensetzungen enthaltend ein opioidanalgetikum - Google Patents

Pharmazeutische zusammensetzungen enthaltend ein opioidanalgetikum

Info

Publication number
DE60335557D1
DE60335557D1 DE60335557T DE60335557T DE60335557D1 DE 60335557 D1 DE60335557 D1 DE 60335557D1 DE 60335557 T DE60335557 T DE 60335557T DE 60335557 T DE60335557 T DE 60335557T DE 60335557 D1 DE60335557 D1 DE 60335557D1
Authority
DE
Germany
Prior art keywords
pharmaceutical compositions
opioidanal
getic
compositions contained
coating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60335557T
Other languages
German (de)
English (en)
Inventor
Benjamin Oshlack
Hua-Pin Huang
Rampurna Gullapalli
Meredith Machonis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Application granted granted Critical
Publication of DE60335557D1 publication Critical patent/DE60335557D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60335557T 2002-08-15 2003-08-15 Pharmazeutische zusammensetzungen enthaltend ein opioidanalgetikum Expired - Lifetime DE60335557D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40371102P 2002-08-15 2002-08-15
PCT/US2003/025601 WO2005007135A1 (en) 2002-08-15 2003-08-15 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
DE60335557D1 true DE60335557D1 (de) 2011-02-10

Family

ID=34078931

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60335557T Expired - Lifetime DE60335557D1 (de) 2002-08-15 2003-08-15 Pharmazeutische zusammensetzungen enthaltend ein opioidanalgetikum
DE60335426T Expired - Lifetime DE60335426D1 (de) 2002-08-15 2003-08-15 Pharmazeutische Zusammensetzungen enthaltend einen Opioidantagonisten

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60335426T Expired - Lifetime DE60335426D1 (de) 2002-08-15 2003-08-15 Pharmazeutische Zusammensetzungen enthaltend einen Opioidantagonisten

Country Status (18)

Country Link
US (2) US20050266072A1 (enExample)
EP (2) EP1542658B1 (enExample)
JP (1) JP4790415B2 (enExample)
KR (1) KR20050086409A (enExample)
CN (1) CN1674873A (enExample)
AT (2) ATE493115T1 (enExample)
BR (1) BR0313627A (enExample)
CA (1) CA2495564A1 (enExample)
CY (2) CY1111825T1 (enExample)
DE (2) DE60335557D1 (enExample)
DK (2) DK1542658T3 (enExample)
ES (2) ES2358151T3 (enExample)
IL (1) IL166561A0 (enExample)
MX (1) MXPA05001826A (enExample)
NZ (1) NZ537763A (enExample)
PT (2) PT1894562E (enExample)
SI (2) SI1542658T1 (enExample)
WO (1) WO2005007135A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
KR20020059653A (ko) 1999-10-29 2002-07-13 그린 마틴, 브라이언 쥐 테슬리 서방성 하이드로코돈 제형
EA004876B1 (ru) 2000-02-08 2004-08-26 Эро-Селтик, С.А. Устойчивые к порче композиции опиоидных агонистов для перорального введения
US6733783B2 (en) 2000-10-30 2004-05-11 Euro-Celtique S.A. Controlled release hydrocodone formulations
US20060264458A1 (en) * 2005-05-03 2006-11-23 Jie Du Quinine dosage forms and methods of use thereof
US20070077313A1 (en) * 2005-10-04 2007-04-05 U.S. Pharmaceutical Corporation Toleration iron supplement compositions
FR2894143B1 (fr) * 2005-12-01 2008-05-02 Pierre Fabre Medicament Sa Composition a liberation prolongee de l'actif, son procede de preparation et son utilisation.
KR100912680B1 (ko) * 2006-03-16 2009-08-19 (주) 벡스코아 제어 방출 제형
US20080119501A1 (en) * 2006-04-28 2008-05-22 Hein William A Immediate release oxymorphone compositions and methods of using same
TW200806282A (en) * 2006-05-05 2008-02-01 Wyeth Corp Solid dosage formulations
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
PT2484346T (pt) * 2006-06-19 2017-04-26 Alpharma Pharmaceuticals Llc Composições farmacêuticas
US7674479B2 (en) 2006-07-25 2010-03-09 Intelgenx Corp. Sustained-release bupropion and bupropion/mecamylamine tablets
US8703191B2 (en) * 2006-07-25 2014-04-22 Intelgenx Corp. Controlled-release pharmaceutical tablets
DK2046300T3 (da) * 2006-08-04 2010-07-26 Ethypharm Sa Oralt desintegrerende multilagstablet
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
BRPI0815387B8 (pt) * 2007-08-13 2021-05-25 Abuse Deterrent Pharmaceutical Llc composição farmacêutica, método para fazer uma composição farmacêutica e uso da composição farmacêutica
CA3066426A1 (en) * 2008-01-09 2009-07-16 Charleston Laboratories, Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
JP2011511782A (ja) 2008-02-12 2011-04-14 アボット・ラボラトリーズ 長期放出性ヒドロコドンアセトアミノフェンならびにその関連方法および用途
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US20110150986A1 (en) * 2009-12-18 2011-06-23 Kristin Arnold Quinine formulations, method of making, and metho of use thereof
EP2568977A1 (en) 2010-05-11 2013-03-20 Cima Labs Inc. Alcohol-resistant metoprolol-containing extended- release oral dosage forms
US10751287B2 (en) * 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
EP2976082A4 (en) 2013-03-15 2016-05-11 Inspirion Delivery Technologies Llc MISS-INFANT COMPOSITIONS AND METHODS OF USE
WO2015023675A2 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
AU2015290098B2 (en) 2014-07-17 2018-11-01 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
CA3055170A1 (en) * 2016-03-04 2017-09-08 Charleston Laboratories, Inc. Pharmaceutical compositions
JP2021512924A (ja) * 2018-02-08 2021-05-20 タイワンジェ ファーマシューティカルズ カンパニー リミテッドＴａｉｗａｎｊ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ．， Ｌｔｄ． オピオイド受容体拮抗薬の固体剤形の医薬製剤
WO2022076470A1 (en) * 2020-10-06 2022-04-14 Sorrento Therapeutics, Inc. Oral delayed burst formulation of low-dose naltrexone or naloxone used for|treating fibromyalgia and long covid
EP4176724A1 (en) 2021-11-09 2023-05-10 Universität Hohenheim Use of an oleogel as a layer or coating

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916889A (en) 1973-09-28 1975-11-04 Sandoz Ag Patient ventilator apparatus
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US5330766A (en) * 1989-01-06 1994-07-19 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5472712A (en) 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5286493A (en) 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5273760A (en) 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
GB9407386D0 (en) * 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
WO1997033581A1 (en) * 1996-03-13 1997-09-18 Yale University Smoking cessation treatments using naltrexone and related compounds
DE19630035A1 (de) * 1996-07-25 1998-01-29 Asta Medica Ag Tramadol Multiple Unit Formulierungen
US6120806A (en) * 1997-06-25 2000-09-19 Whitmire; David R. Oral formulations for controlled release of alcohol deterrents
RS49982B (sr) * 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
US6274591B1 (en) * 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
US6375957B1 (en) * 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
AU773642C (en) * 1997-12-22 2006-04-06 Mundipharma Pty Limited Opioid agonist/antagonist combinations
US6270805B1 (en) * 1998-11-06 2001-08-07 Andrx Pharmaceuticals, Inc. Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate
US6765010B2 (en) * 1999-05-06 2004-07-20 Pain Therapeutics, Inc. Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects
EA004876B1 (ru) * 2000-02-08 2004-08-26 Эро-Селтик, С.А. Устойчивые к порче композиции опиоидных агонистов для перорального введения
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
EP1284736A2 (en) * 2000-05-05 2003-02-26 Pain Therapeutics, Inc. Opioid antagonist compositions and dosage forms
US7144587B2 (en) * 2001-08-06 2006-12-05 Euro-Celtique S.A. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
WO2003013433A2 (en) * 2001-08-06 2003-02-20 Euro-Celtique S.A. Sequestered antagonist formulations
KR20040060917A (ko) * 2001-08-06 2004-07-06 유로-셀티크 소시에떼 아노뉨 오피오이드 남용을 방지하기 위한 조성물 및 방법
US7842307B2 (en) * 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
US7332182B2 (en) * 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
NZ530971A (en) * 2001-08-06 2004-08-27 Euro Celtique S Oral dosage forms comprising an opioid agonist with releasable and sequestered opioid antagonists
AU2003220290B2 (en) * 2002-03-14 2007-06-14 Euro-Celtique S.A. Naltrexone hydrochloride compositions
US20030191147A1 (en) * 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
WO2004071423A2 (en) * 2003-02-05 2004-08-26 Euro-Celtique S.A. Methods of administering opioid antagonists and compositions thereof
TWI347201B (en) * 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same

Also Published As

Publication number Publication date
PT1542658E (pt) 2011-02-03
CY1111821T1 (el) 2015-10-07
US20050266072A1 (en) 2005-12-01
KR20050086409A (ko) 2005-08-30
EP1894562A1 (en) 2008-03-05
IL166561A0 (en) 2006-01-15
ATE491439T1 (de) 2011-01-15
WO2005007135A1 (en) 2005-01-27
SI1542658T1 (sl) 2011-04-29
SI1894562T1 (sl) 2011-04-29
DE60335426D1 (de) 2011-01-27
EP1542658A4 (en) 2006-04-05
CA2495564A1 (en) 2005-01-27
DK1894562T3 (da) 2011-03-28
DK1542658T3 (da) 2011-04-04
EP1542658A1 (en) 2005-06-22
CN1674873A (zh) 2005-09-28
BR0313627A (pt) 2005-06-21
ATE493115T1 (de) 2011-01-15
JP2006514988A (ja) 2006-05-18
JP4790415B2 (ja) 2011-10-12
CY1111825T1 (el) 2015-10-07
PT1894562E (pt) 2011-01-14
ES2358896T3 (es) 2011-05-16
US20160317456A1 (en) 2016-11-03
NZ537763A (en) 2006-08-31
MXPA05001826A (es) 2005-04-19
ES2358151T3 (es) 2011-05-06
HK1088211A1 (en) 2006-11-03
EP1542658B1 (en) 2010-12-29
EP1894562B1 (en) 2010-12-15

Similar Documents

Publication Publication Date Title
DE60335557D1 (de) Pharmazeutische zusammensetzungen enthaltend ein opioidanalgetikum
ATE307571T1 (de) Pharmazeutische formulierung enthaltend bicalutamid
PT1183014E (pt) Composicoes farmaceuticas orais de libertacao controlada e de dissimulacao de sabor
ITTO20010005A1 (it) Formulazione farmaceutica.
ATE513541T1 (de) Pharmazeutische zusammensetzungen zur oralen verabreichung von calcitonin
ATE405630T1 (de) Wirkstoffabgabesysteme
BR0207025B1 (pt) derivado de isoxazolina e herbicida contendo o mesmo como o ingrediente ativo.
IL163552A (en) Conjugates of biologically active compounds, uses thereof and pharmaceutical compositions comprising the same
MA26033A1 (fr) Agent active de livraison aerosol
DE69904312D1 (de) Pharmazeutische aerosolformulierung
BRPI0013439B8 (pt) composiÇço compreendendo tramadol e um fÁrmaco anticonvulsivante.
DE60312049D1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff
ID27504A (id) Formulasi oral baru
FI4823U1 (fi) Muunnetulla tavalla vapauttava lääkeformulaatio
ITMI20011401A0 (it) Formulazioni farmaceutiche per ormoni tiroidei
DE59907481D1 (de) Kontrolliert freisetzende pharmazeutische zusammensetzung mit tilidinmesylat als wirkstoff
ATE350016T1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
DE10084344T1 (de) Cyclosporin enthaltende pharmazeutische Zusammensetzung
DE10192797D2 (de) Drug-Delivery-Systeme
FR2820311B3 (fr) Distributeur de medicament portatif
DE10291905D2 (de) Pharmazeutische Zusammensetzung
ATE350029T1 (de) Pharmazeutische zusammensetzung enthaltend gamma- butyrobetain
DE10107261B4 (de) Pharmazeutische Zusammensetzung
DK1275383T3 (da) "Modified release" farmaceutisk komposition, der indeholder Bupropion HCI som aktivt stof
ITMI20011390A1 (it) Formulazioni farmaceutiche per ormoni tiroidei.